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16Objective: Outcomes assessing various treatment modalities for esophageal cancer primarily report results in
terms of morbidity, mortality, survival, and quality of life. The most appropriate stage-by-stage treatment for
esophageal cancer remains controversial. There are limited data outlining the comparative costs of surgical,
combined modality and definitive chemoradiation treatments, and added costs associated with complications.
Methods: Between 2000 and 2004, 4 treatment groups were studied: surgery alone, chemotherapy followed by
surgery, chemoradiotherapy followed by surgery, and chemoradiotherapy alone. Fifteen consecutive patients
from each group receiving their entire treatment at Virginia Mason Medical Center were identified. Patient de-
mographics and outcomes were taken from a prospective institutional review board-approved surgical database,
and chart review obtained information for neoadjuvant therapy and definitive chemoradiotherapy groups.
Treatment-related costs were extracted from Virginia Mason Medical Center’s financial data management sys-
tem between date of diagnosis to 90 days after completion of primary therapy.
Results: Treatment groups were similar in age, gender ratio, American Society of Anesthesiologists status, body
mass index, and tumor cell type. Costs increased with the number of treatment modalities: surgery alone,
$33,517; chemotherapy followedbysurgery, $41,875; chemoradiotherapy followedby surgery, $47,389;andchemo-
radiotherapy alone, $46,659. Treatment-related complicationswere surgery alone, 47%; chemotherapy followed by
surgery, 64%; chemoradiotherapy followed by surgery, 66%; and chemoradiotherapy alone, 87% (P¼ .139). Com-
plications increased costs in all groups: surgery alone, 26% (P ¼ .008); chemotherapy followed by surgery, 23%
(P¼ .001); chemoradiotherapy followed by surgery, 9% (P¼ .702); and chemoradiotherapy alone, 19% (P¼ .248).
Conclusions: Costs vary significantly among treatment approaches: surgery alone costs 80% of chemotherapy
and surgery, 71% of chemoradiotherapy and surgery, and 72% of chemoradiotherapy alone. Costs of tri-
modality therapy and definitive chemoradiotherapy are similar. Especially in the absence of definitive
evidence-based data, these costs should be a factor in the production of future national treatment guidelines. De-
creasing costs requires future quality initiatives in esophageal cancer treatment that focus on minimizing com-
plications related to treatment. (J Thorac Cardiovasc Surg 2011;141:16-21)The most recent statistics demonstrate that esophageal can-
cer continues to increase in incidence, especially inmen, de-
spite an overall decrease in cancer incidence nationally.1
The prognosis associated with esophageal cancer remains
poor, and the surgical management of esophageal cancer
has historically been associated with a higher incidence of
surgical mortality compared with other major oncologic
procedures2 and complications.3 There is a continuing con-e Department of Thoracic Surgery and Thoracic Oncology, Virginia Mason
cal Center, Seattle, Wash.
res: Authors have nothing to disclose with regard to commercial support.
the 36th Annual Metting of The Western Thoracic Surgical Association,
California, June 23–26, 2010.
d for publication June 26, 2010; revisions received Aug 26, 2010; accepted
blication Sept 8, 2010; available ahead of print Nov 8, 2010.
for reprints: Donald E. Low, FACS, FRCS(c), Section of General Thoracic
ry, Virginia Mason Medical Center, 1100 Ninth Ave C6-SUR, Seattle, WA
(E-mail: gtsdel@vmmc.org).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.09.011
The Journal of Thoracic and Cardiovascular Surgetroversy regarding the most appropriate stage-by-stage
management of patients with esophageal cancer.4 This con-
troversy is intensified in an erawhen advances in endoscopic
treatment techniques, advances in medical and radiation on-
cology results, and the introduction of minimally invasive
surgical procedures make the accumulation of evidence-
based data to specifically direct therapy more challenging.
Recent in-depth analysis of randomized controlled trials
confirms the limited availability of level I evidence to defin-
itively guide therapy in many stages of esophageal cancer.5
This has led to significant differences in the approach to
esophageal cancer treatment within national and regional
health systems, and even between individual practitioners.
Patients, government, private payors, and medical systems
increasingly are looking to justify the application of limited
financial resources. Analysis of outcomes in cancer care has
typically focused on disease-free and overall survival,
treatment-related complications, mortality, and post-
therapy quality of life. The cost of cancer treatment has
not typically been a component of outcomes assessmentry c January 2011
Abbreviations and Acronyms
CR ¼ chemoradiotherapy alone
CRS ¼ adjuvant chemoradiotherapy followed by
surgery
CS ¼ adjuvant chemotherapy followed by
surgery
S ¼ surgery alone
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rate cost data comparing the economic differences in current
treatment regimens has not been available. The goal of this
study is to accurately document the current true costs asso-
ciated with surgery, multi-modality therapy, and definitive
chemoradiotherapy at the Virginia Mason Medical Center.
We believe these data will provide a valuable resource
as national treatment guidelines for esophageal cancer
continue to evolve and allocation of health care financial
resources comes under increasing scrutiny.
MATERIALS AND METHODS
At a high-volume, tertiary-referral, resident-training esophageal center,
the currentmost commonapproaches to the treatment of invasive esophageal
cancer were identified. These were surgery alone (S), adjuvant chemother-
apy followed by surgery (CS), adjuvant chemoradiotherapy followed by sur-
gery (CRS), and chemoradiotherapy alone (CR). In 2000, a financial cost-
accounting system was introduced (Alliance Decision Support MedAssets,
Inc, Atlanta, Ga), allowing individual identification and tracking of all costs
associated with treatment. TheAllianceDecision Support System allows the
Virginia Mason Medical Center to identify all fully loaded costs associated
with direct and indirect expenses. Direct costs are broken down to 7 cost
components, including salaries and benefits, drugs, andmedical supplies. In-
direct costs (institution overhead costs) are a complex association of all over-
head, including billing, information systems, finance, and administration.
Starting in 2000, 15 consecutive patients in each treatment group who
had received their entire treatment at Virginia Mason Medical Center
were identified. S, CS, and CRS groups were all treated between 2000
and 2002, whereas the CR group received therapy between 2000 and
2004. All surgical procedures were open transthoracic operations, either
left thoracoabdominal or Ivor Lewis. More than 90% of chemotherapy
in all groups during this era typically involves 2 to 4 cycles of cisplatin
and 5FU with radiotherapy doses typically of 5940 cGy for the CR group
and 4500 to 5040 cGy for the CRS group.
Patient and outcome demographics of the S, CS, and CRS groups were
prospectively recorded in an institutional review board-approved database.
The CR group was identified through the cancer registry and cancer depart-
ment database and underwent a retrospective review of their chart and can-
cer center records.
All inpatient and outpatient costs were recorded from the time of diag-
nosis to 90 days after completion of therapy. Cost assessment included doc-
umenting resources required for diagnosis, staging, primary treatment of
esophageal cancer, treatment of complications, and post-treatment fol-
low-up and assessment. The study was reviewed and accepted by our insti-
tutional investigational review board.
Statistics
Descriptive statistical methods were used to evaluate clinical character-
istics and cost differences for each management strategy. Each group’s costThe Journal of Thoracic and Cand relevant clinical characteristics were compared using Student t tests,
Pearson’s chi-square tests (nonparametric tests), and analysis of variance.
Statistical analysis was carried out using the PASW version 18 (SPSS,
Inc, Chicago, ll).
The Challenge of Obtaining Accurate Cost Data
Understanding the cost of delivering medical services is increasingly
recognized as an important aspect in the delivery of national medical ser-
vices and the appropriate use of medical resources. Charges are a poor sur-
rogate6,7 for comparison because of significant variance among
international, regional, and individual institutions. Many previous cost
studies have used cost-to-charge ratios6,8 rather than specific cost data for
delivering services. Obtaining cost data is likely more straightforward in
countries with national or centralized health systems. In the United
States, however, there is no central infrastructure to negotiate contracts
with suppliers or coordinate treatment approaches or reimbursement. Up
to this point, the most accurate method of tracking resource use and costs
has been the application of a detailed cost accounting system, such as
Transitions System, Inc, which can track resources but assigns estimates
of costs.9,10
The Alliance costing system has been used at Virginia Mason Medical
Center since 2000. The system tracks actual costs but has an 18-month de-
lay until data are complete. This enabled us to examine specific actual costs
in our different treatment groups. However, accuracy is contingent on en-
suring ‘‘all’’ treatment is delivered in a single medical system. This issue is
becoming more pertinent in an era when patients are motivated to travel,
often long distances, to high-volume centers for complex cancer therapy.
In addition, consistent assessment of costs is more challenging when treat-
ment delivery often occurs over many months and involves multiple med-
ical and surgical subspecialties.
In our study group, which received chemoradiotherapy plus surgery, we
had to screen 90 patients to find 15 who had received their entire treatment
regimen at Virginia Mason Medical Center and therefore would have
a complete cost accounting. Accurate overall assessment of outcomes is
best when the cost assessment is done in conjunction with a preexistent pro-
spective database, which was the case in 3 of 4 of our treatment groups.
In addition, considering that the period of assessment typically extends
between 4 and 12 months depending on the treatment approach, the cost
data must be carefully screened to eliminate nontreatment costs, such as
health maintenance or treatment of unrelated conditions. This process is
time-intensive, but ultimately leads to the data being as accurate as possible
and superior to results obtained in studies using charge-to-cost ratios or ex-
trapolating costs according to relative value units.7RESULTS
Appropriate consecutive patients were identified in all
surgery groups between 2000 and 2002, and the CR group
was accrued between 2000 and 2004. During the 3 years
in which surgical patients were accrued, a mean of 33 resec-
tions per year were performed. Table 1 demonstrates the ba-
sic characteristics of each patient group. Except for the
expected differences in clinical stage between treatment
modalities, there were no significant differences noted in
age, gender ratio, presenting body mass index, American
Society of Anesthesiologists, or tumor cell type. There
was a trend toward a higher incidence of treatment-related
complications in the CR group, but this did not reach statis-
tical significance. Hospital length of stay and weight loss
more than 10 lbs was significantly greater in the CR group
than in the surgical groups. Table 2 shows total costs andardiovascular Surgery c Volume 141, Number 1 17
TABLE 1. Demographics of patients in individual treatment groups
Surgery
alone
Chemotherapy
and surgery
Chemoradiotherapy
and surgery
Chemoradiotherapy
alone P
Patients (n) 15 15 15 15
Mean age (y) 66 60 62 62 .103
Age>65 (n) 8 6 6 5 .729
Male (n) 13 14 15 14 .543
ASA 3–5 (n) 7 10 11 13 .123
Mean BMI 27 28 25 23 .461
BMI>30 (n) 5 4 2 2 .449
Pretreatment weight loss>10 lbs (n) 3 3 7 11 .007
Tumor type: adenocarcinoma 14 14 15 13 .450
Clinical stage (n) .001
I 8
II 5 11 5
III 2 4 10 7
IV 8
Inpatient hospital days (range) 8 (7–30) 9 (6–17) 10 (7–18) 14 (9–18) .024
Treatment-related complications 7 9 10 13 .139
ASA, American Society of Anthesiologists; BMI, body mass index.
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creased as the number of therapeutic modalities increased,
with the S group having the lowest cost ($33,517) and the
CRS group being the most expensive ($47,389). Costs-to-
charge ratios varied between 2.12 and 2.36, indicating
that this methodology could provide an approximate esti-
mation of costs in the absence of specific cost data. How-
ever, Table 2 shows that different conversion ratios would
be required in our institution between surgical and nonsur-
gical patients. Surgery alone produced costs equaling 72%
of CR, 80% of CS, and 71% of CRS groups. Statistically
significant differences were noted in costs between surgery
and chemoradiotherapy followed by surgery (P¼ .028) and
between surgery alone and definitive chemoradiation
(P ¼ .015). No other significant differences were noted be-
tween treatment groups. The costs of the CRS and CR
groups were similar: $47,389 and $46,659, respectively
(P ¼ .907).
Table 3 outlines the differences in costs in patients who
experience treatment-related complications. As expected,
complications increased costs in all treatment groups. In-
creases were significant in the S and CS groups. The failure
to identify a significant difference in the cost effect of com-
plications in the other 2 groups is likely related to the rela-
tively small number of patients (CR 2, CRS 5) who did notTABLE 2. Comparison of costs, charges, and cost to charge ratios
Treatment group Mean cost ($)
Standard
deviation ($
Surgery alone 33,517 13,059
Chemotherapy and surgery 41,875 10,527
Chemoradiotherapy and surgery 47,389 19,077
Chemoradiotherapy only 46,659 14,592
18 The Journal of Thoracic and Cardiovascular Surgeexperience complications at some point during treatment.
Individual complications are shown in Table 4. Patients
having multiple treatment-related complications were com-
mon. No anastomotic or chyle leaks were documented in
any of our surgical groups, and no patients died of cancer,
treatment-related causes, or unrelated causes during the pe-
riod of study. The only stage represented in all 4 treatment
groups was stage III. However, the number of patients with
stage III cancer in groups S (2) and CS (4) was small, mak-
ing specific comparisons potentially inaccurate.
DISCUSSION
In an assessment of health care expenditures published in
2010, the cost of delivering health care in the United States
in 2005 was approximately 2 trillion dollars or 16% of
gross domestic product. Health expenditures are increasing
at 2½ times the rate of the general economy,11 which is
clearly unsustainable. Health care reform and, more perti-
nently, fiscal requirements will necessitate analyzing cost
in addition to standard treatment outcome parameters in fu-
ture national treatment guidelines and with respect to the fu-
ture allocation of health care dollars.
This analysis will be more important in treatment regi-
mens for which definitive evidence-based treatment guide-
lines are unavailable or incomplete, especially in clinical) Range ($)
Mean
charges ($)
Cost to charge
ratio
15,584–61,242 78,136 2.33
24,668–58,216 98,763 2.36
22,764–95,955 111,965 2.36
25,410–73,607 98,984 2.12
ry c January 2011
TABLE 3. Effect of complications on costs
Complication
Overall mean
cost ($)
% increase in overall
cost for patients
with complications P
No Yes
N
Mean
cost ($) N
Mean
cost ($)
Surgery alone 8 29,522 7 38,082 33,517 25.5% .008
Chemotherapy and surgery 6 36,021 9 45,778 41,875 23.3% .001
Chemoradiotherapy and surgery 5 44,577 10 48,795 47,389 8.9% .702
Chemoradiotherapy only 2 38,833 13 47,863 46,659 19.4% .248
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lars in individual patients.
The stage-by-stage treatment of esophageal cancer re-
mains diverse because of the absence of level 1 evidence to
direct therapy4,5 and varying regional perceptions of the
consequences of surgical therapy.2,3 These perceptions
have been confirmed with an analysis of the SEER national
database confirming that surgery is currently underused in
the treatment of all stages of esophageal cancer in the
United States.12 Individual treatment recommendations canTABLE 4. Number of patients with complications (n)
Surgery
alone
Chemotherapy
surgery
Single complication 1 5
Multiple complications 8 4
Total complications 11 13
Cardiac
Atrial fibrillation 1 4
MI
CHF
Pericardial effusion
Pulmonary
Pneumonia 1 1
Pleural Eff
Req Rx 1 2
Pneumothorax
Req Rx 1
Reintubation
Respiratory failure
Other
GI
Ileus 2 1
SBO 1
GI bleeding
Urinary 1 2
Delirium 3
Wound infection 2
Reoperation 1
Dehydration
Hematologic
Vascular (DVT/PE)
Other
MI, Myocardial infarction; CHF, congestive heart failure; SBO, small bowel obstruction;
The Journal of Thoracic and Cvary significantly depending on the practitioner or medical
system a patient initially contacts. Patients with T1a disease
may have endoscopic, surgical, or definitive chemoradiother-
apy as their initial treatment recommendation.4,13,14 As
confirmed in this study, patients with stage II or III disease
can be recommended for surgery alone, neoadjuvant
therapy and surgery, or definitive chemoradiotherapy.5,15,16
Patients who are not surgical candidates because of poor
physiology may be recommended for chemotherapy,
chemoradiation, or palliative care. National ComprehensiveChemoradiotherapy
surgery
Chemoradiotherapy
alone
4 2
6 11
16 32
3 2
1
2
2
5
2 2
1
1
1
1
1
1
3
2
4
4
2 2
1 5
GI, gastrointestinal; DVT/PE, deep vein thrombosis/pulmonary embolism.
ardiovascular Surgery c Volume 141, Number 1 19
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SCancer Network guidelines exist to direct therapy in patients
with cancer.17 However, the consistency of the delivery of
treatment in esophageal cancer within the United States re-
mains open to individual interpretation, and current guide-
lines do not typically include costs in the formulation of
the recommendations often because accurate data do not
exist.
Surgical treatment of esophageal cancer has experienced
particular scrutiny within medical circles but also by con-
sumer groups, such as Leapfrog (www.leapfrog.com),
because of higher levels of complications3 and mortality.2
Previous studies have clearly demonstrated that complica-
tions increase the cost of therapy.8,9,18-21 Other reports
highlight that comorbidities and surgical complexity also
lead to higher costs,18 which is particularly germane in
patients treated for esophageal cancer.
Limiting complications is clearly a major factor in con-
trolling costs. Dimick and colleagues9 showed the financial
impact of complications in a wide variety of surgical proce-
dures at a single medical center involved in the National
Surgery Quality Improvement Program. Consistent with
our findings, they demonstrate that major complications in-
crease costs an average of more than $11,000. They appro-
priately concluded that quality initiatives that minimize the
incidence of complications would have a direct effect on
treatment-related costs.19 Previous cost assessments in the
treatment of esophageal cancer have been of limited appli-
cation because they focus on only a component of the treat-
ment options or cost data are estimated or incomplete.20
The results of the current study are taken from actual
costs of delivering the specified treatment. This is an ex-
tremely labor-intensive process and not applicable in larger
single-center or national database reviews, but in this in-
stance it does provide a rare insight into actual costs of
the 4 current treatment approaches to invasive esophageal
cancer at Virginia MasonMedical Center. Except for differ-
ences in clinical stage, the 4 groups were similar.
There is a perception that chemoradiation therapy is safer
than surgical treatment. In addition, esophagectomy has
a well-earned reputation for post-treatment complications.
It is possible that some of the cost and complications differ-
ences noted, especially in the CR group, were associated
with more advanced stage and poorer performance status,
as reflected in greater pretreatment weight loss (Table 1).
However, all 3 surgical groups had numerically fewer
treatment-related complications than the definitive chemo-
radiation group. The definitive chemoradiotherapy group
did have significantly greater pretreatment weight loss
than the surgical groups; however, the CR group also re-
quired significantly more in-hospital days than the groups
receiving surgery alone or multimodality treatment. The S
group had the lowest overall incidence of complications
and generates costs only 72% of those seen in definitive
chemoradiotherapy.20 The Journal of Thoracic and Cardiovascular SurgeThere is an evolving interest in comparing surgery alone
with definitive chemoradiotherapy in all stages of esopha-
geal cancer, but particularly in early stage I and IIA.15
Mak and colleagues21 documented that, especially in older
patients, chemoradiation can be associated with grade IV
toxicity in 40% and hospitalizations and treatment interrup-
tions in 70%. They also showed that in patients aged more
than 75 years, the mortality rate was 12%, which is higher
than seen in comparable surgical series.22,23 Our data
suggest that even while acknowledging differences in
stage and performance status in specialized centers,
surgery has a potential advantage from the perspective of
treatment-related complications, hospital length of stay,
and costs. This issue should be part of future comparisons
of these 2 treatment approaches. Mortality could not be as-
sessed, because there were no deaths in any treatment group
during this study.
Surgery alone also used fewer resources and cost only
80% of chemotherapy plus surgery and 71% of chemora-
diation plus surgery. Although current treatment trends in
North America and Europe favor neoadjuvant treatment,
the most recent reviews of best available evidence are not
definitive in their support of multi-modality treatment.5,24
Future formulation of national treatment guidelines
should include assessments of cost-effectiveness, as well
as treatment efficacy and safety.
In the shorter term, however, payors are likely to demand
amore specific cost assessment of treatment approaches, es-
pecially when definitive treatment guidelines do not exist or
are not supported by evidence-based clinical data. Current
growth in health care expenditures is not sustainable in
the long-term.11 This issue goes further than simple cost
analysis because, increasingly, measurements of treatment
outcomes are focusing on regional and national assessments
of quality, which are directly associated with limiting the in-
cidence of treatment-related complications.9,19 The current
study demonstrates that complications increase costs
between 9% and 25%. Patients with treatment-related
complications consume more resources and demonstrate
higher mortality rates and poorer post-treatment quality of
life.3,19 Under diagnosis-related group and capitated reim-
bursement programs, complications affect institutional
and medical system profit margins, but the greatest burden
has historically fallen on payors, both government and pri-
vate, who experience increased costs when complications
occur.19 However, there is an increasing trend toward shift-
ing this burden more toward medical systems. This is most
evident with the Centers for Medicare and Medicaid
Services’ recent passage of hospital-acquired conditions
legislation and the subsequent adoption of the payment pro-
vision(s) by major insurance companies.25-27 In the future,
payors (both government and private) will increasingly
use quality and cost data to guide decisions regarding
health-related resource allocation, especially in high-riskry c January 2011
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ing patients to recognized centers of excellence that can
demonstrate the ability to limit complications and control
cost expenditures. It may also be an instigating factor for in-
dividual medical systems deciding which highly complex
medical procedures they will provide.
The potential weakness of this study is the relatively
small number of patients in each study group. However,
our goal was to provide an actual rather than estimated in-
dication of true costs. This assessment included only pa-
tients who had their entire treatment at a single medical
center, which, considering the complexity of current treat-
ment and the increasing use of regional referral centers, is
becoming more uncommon. These patients had assessment
of all inpatient, outpatient, direct, and indirect costs, and un-
derwent a labor-intensive screening to remove all
nontreatment-related costs, resulting in this report provid-
ing a financial perspective more accurate than its predeces-
sors.
CONCLUSIONS
This study provides as accurate as possible expression of
the true costs of the various treatment approaches to esoph-
ageal cancer and confirms the significant economic effect of
complications on the cost of delivering treatment. These
data should be considered in the continued evolution of na-
tional treatment guidelines for the treatment of esophageal
cancer.
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